{"id":2732,"date":"2025-03-18T11:52:14","date_gmt":"2025-03-18T11:52:14","guid":{"rendered":"https:\/\/genosophy.gr\/product\/gunaikologikes-kakoitheies-kai-klironomikos-karkinos-tou-mastou-2\/"},"modified":"2025-04-24T13:19:14","modified_gmt":"2025-04-24T13:19:14","slug":"gunaikologikes-kakoitheies-kai-klironomikos-karkinos-tou-mastou-2","status":"publish","type":"product","link":"https:\/\/genosophy.gr\/en\/product\/gunaikologikes-kakoitheies-kai-klironomikos-karkinos-tou-mastou-2\/","title":{"rendered":"Gynecological Malignancies and Hereditary Breast Cancer"},"content":{"rendered":"<p>Gynecological cancers can have a hereditary basis, particularly in cases of <strong>ovarian<\/strong>, <strong>endometrial<\/strong>, and <strong>cervical cancer<\/strong>.<\/p>\n<p>For example, the <strong>Hereditary Breast and Ovarian Cancer (HBOC) Syndrome<\/strong> is associated with pathogenic variants in the <strong>BRCA1<\/strong> and <strong>BRCA2<\/strong> genes, while <strong>Lynch Syndrome (HNPCC)<\/strong> is linked to mutations in <strong>DNA mismatch repair genes<\/strong> such as <strong>MLH1, MSH2, MSH6, PMS2<\/strong>, and <strong>EPCAM<\/strong>.<\/p>\n<p>The <strong>GENOSOPHY\u00ae Genetic Testing Panel for Gynecological Malignancies<\/strong> analyzes <strong>29 genes<\/strong> associated with the development of gynecological and breast cancers and is essential for:<\/p>\n<ul>\n<li>Differential diagnosis between <strong>sporadic<\/strong> and <strong>hereditary<\/strong> forms of cancer<br \/>\n\u2022 <strong>Risk assessment<\/strong> and <strong>screening<\/strong> of high-risk families<br \/>\n\u2022 <strong>Personalization<\/strong> of the therapeutic approach<\/li>\n<\/ul>\n<h3>Conditions Covered by the GENOSOPHY\u00ae Gynecological Cancer Panel<\/h3>\n<ul>\n<li><strong>Hereditary Ovarian Cancer<\/strong> (HBOC Syndrome \u2013 BRCA1\/2)<\/li>\n<li><strong>Endometrial Cancer<\/strong> (Lynch Syndrome \u2013 MLH1, MSH2, MSH6, PMS2, EPCAM)<\/li>\n<li><strong>Li-Fraumeni Syndrome<\/strong> (TP53) \u2013 Increased risk for multiple cancer types<\/li>\n<li><strong>Peutz-Jeghers Syndrome<\/strong> (STK11) \u2013 Ovarian and cervical cancer<\/li>\n<li><strong>Cowden Syndrome<\/strong> (PTEN) \u2013 Elevated risk for breast and endometrial cancer<\/li>\n<\/ul>\n<h3>Clinical Benefits<\/h3>\n<h4>Diagnosis<\/h4>\n<ul>\n<li>Detection of pathogenic genetic variants associated with hereditary gynecological cancers<\/li>\n<li>Distinction between <strong>sporadic<\/strong> and <strong>inherited<\/strong> forms of cancer<\/li>\n<\/ul>\n<h4>Prognosis<\/h4>\n<ul>\n<li>Evaluation of cancer development risk and preventive strategy<\/li>\n<li>Family risk assessment and <strong>genetic counseling<\/strong><\/li>\n<\/ul>\n<h4>Management<\/h4>\n<ul>\n<li>Guidance on personalized monitoring and <strong>prophylactic surgery<\/strong><\/li>\n<li>Pharmacogenetic approach (e.g., <strong>PARP inhibitors<\/strong> for BRCA mutation carriers)<\/li>\n<\/ul>\n<h3>Testing Process<\/h3>\n<ol>\n<li>Collection of a <strong>blood or saliva sample<\/strong><\/li>\n<li><strong>Analysis of 29 genes<\/strong> associated with gynecological malignancies using <strong>Next Generation Sequencing (NGS)<\/strong><\/li>\n<li><strong>Results available in approximately 5 weeks<\/strong><\/li>\n<\/ol>\n<p>Interpretation and counseling of results is also available from Professors at the <strong>Medical School of the National and Kapodistrian University of Athens (EKPA)<\/strong> as an optional service.<\/p>\n<h3>Genes Included in the Test<\/h3>\n<p><strong>ATM, BARD1, BLM, BRCA1*, BRCA2, BRIP1, CDH1, CHEK2*, DICER1*, EPCAM, FANCM, MAP3K1, MLH1, MRE11A, MSH2, MSH6, NBN, NF1*, PALB2, PMS2*, PTEN*, RAD50, RAD51C, RAD51D, RECQL*, SMARCA4, STK11, TP53, XRCC2<\/strong><\/p>\n<p><strong>Note<\/strong>: In addition to sequencing all coding exons, the GENOSOPHY\u00ae test analyzes multiple variants in <strong>non-coding regions<\/strong> such as promoters and introns. The sensitivity for detecting <strong>single nucleotide variants (SNVs)<\/strong>, <strong>indels<\/strong>, and <strong>copy number variations (CNVs)<\/strong> is &gt;99%. Detection sensitivity may be slightly reduced for genes marked with an asterisk (*).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gynecological cancers can have a hereditary basis, particularly in cases of ovarian, endometrial, and cervical cancer. For example, the Hereditary Breast and Ovarian Cancer (HBOC) Syndrome is associated with pathogenic variants in the BRCA1 and BRCA2 genes, while Lynch Syndrome (HNPCC) is linked to mutations in DNA mismatch repair genes such as MLH1, MSH2, MSH6, [&hellip;]<\/p>\n","protected":false},"featured_media":2462,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[85],"product_tag":[],"class_list":{"0":"post-2732","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-oncologic-ipiresies-gia-epaggelmaties-en","8":"first","9":"instock","10":"taxable","11":"shipping-taxable","12":"product-type-simple"},"acf":[],"_links":{"self":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product\/2732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/media\/2462"}],"wp:attachment":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/media?parent=2732"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_brand?post=2732"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_cat?post=2732"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_tag?post=2732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}